LOCAL-CONTROL OF T3 CARCINOMAS AFTER ACCELERATED FRACTIONATION - A LOOK AT THE GAP

Citation
Cc. Wang et al., LOCAL-CONTROL OF T3 CARCINOMAS AFTER ACCELERATED FRACTIONATION - A LOOK AT THE GAP, International journal of radiation oncology, biology, physics, 35(3), 1996, pp. 439-441
Citations number
7
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
ISSN journal
03603016
Volume
35
Issue
3
Year of publication
1996
Pages
439 - 441
Database
ISI
SICI code
0360-3016(1996)35:3<439:LOTCAA>2.0.ZU;2-#
Abstract
Purpose: To study the effects of midcourse treatment break or gaps rel ated to the local control of T3 carcinoma of the oropharynx and larynx following accelerated hyperfractionated radiation therapy. Methods an d Materials: All patients were treated at the Massachusetts General Ho spital from 1979 through 1994 with treatment consisting of 1.6 Gy per fraction, two fractions a day for the treatment of T3 carcinoma of the oropharynx and larynx. They were entered in the head and neck data ba se, Their treatment dates, treatment breaks, and doses vs, local contr ol were analyzed and compared, A p-value of 0.05 was considered statis tically significant. Results: A total of 162 patients were available f or review, Due to the acute severe mucosal effects, most of the patien ts required a midcourse pause or ''break'' after a dose of 38.4-48 Gy before treatment could be resumed and completed, The data indicate tha t (a) prolongation of the treatment gap for more than 14 days, (b) tot al treatment course longer than 45 days, (c) total dose less than 67 G y, and (d) male gender adversely affected local control. In spite of t he gaps, the female patients with advanced carcinomas enjoyed the bene fits of improved local control after the accelerated hyperfractionated radiation therapy. Conclusions: Accelerated hyperfractionation radiat ion therapy using 1.6 Gy per fraction/twice-a-day (b.i.d.) for a total dose of 70.4 Gy in 6 weeks is effective in achieving high local contr ol of T3 squamous cell carcinoma of the oropharynx and larynx. The mid course treatment gap should be as short as possible with the projected total dose and time, Should the gaps be unduly prolonged due to vario us circumstances, further increase in the total dose, for example, 72- 75 Gy, and/or increase of the fraction sizes, for example, 1.8-2.0 Gy/ f b.i.d. after the gap may be necessary to compensate for the adverse effects of the tumor regeneration from the prolonged gap.